Thalidomide in Mucosa Associated Lymphoid Tissue (MALT) Lymphoma Patients

• Status: Completed
• Trial end date: 2009-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate Thalidomide for treatment of disseminated MALT Lymphoma or at relapse following helicobacter pylori (HP) - eradication or chemotherapy or radiation.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Medical University of Vienna
• Treatments: Thalidomide

Criteria

Inclusion Criteria:

• Patients with histologically confirmed MALT lymphoma with measurable disease (Stage I-IV)

• With first or greater relapse after HP-eradication, radiation or chemotherapy

• Age > 18

• Must be able to tolerate therapy and have adequate cardiac, renal and hepatic function

• ECOG status _< 2

• Must be capable of understanding the purpose of the study and have given written informed consent